Search

Background: Calprotectin is an important molecule in the initiation and progression of the inflammatory process. Systemic and local intraperitoneal inflammation are distinct processes and consequences in peritoneal dialysis (PD). We aimed to evaluate dialysate calprotectin levels and its associations with peritonitis and dialysis adequacy in PD patients. Methods: Forty‐four PD patients were included in this prospective study. Calprotectin concentration was evaluated in 24‐h peritoneal drainage fluid. Patients were followed‐up for 1 year, and peritonitis episodes were recorded. Dialysate calprotectin levels were compared to dialysis adequacy parameters and peritonitis frequency. Results: The mean age of patients was 54.9±12.7 years. Median PD duration was 54 (23–76) months. Seventeen patients (38.6%) had previous peritonitis episodes. During follow‐up, 15 of 44 patients (34.1%) had peritonitis. The median calprotectin concentration was 79.5 (75.2–86.3) ng/ml. The patients were divided into low and high calprotectin groups according to median value. In the high calprotectin group, BMI was found higher (p = 0.04). There was no significant relationship between calprotectin concentration and peritonitis during follow‐up (p = 0.29). However, the patients that have had previous peritonitis had higher calprotectin concentrations (p = 0.02). The patients who had higher erythrocyte sedimentation rate (ESR) levels also had higher calprotectin concentrations (p = 0.01). Conclusion: Peritoneal calprotectin concentrations were correlated with higher BMI and ESR, and it was higher in patients with previous peritonitis episodes. To our knowledge, this is the first study to examine the peritoneal calprotectin levels in PD patients. Further studies are needed to determine the use of peritoneal calprotectin as an inflammatory marker in PD. [ABSTRACT FROM AUTHOR]